Practice-changing trials to watch for in 2018

FAQ Library published on January 24, 2018
Download Transcript Download Audio
Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Welcome to Managing Myeloma. I am Dr. Sagar Lonial. What I want to spend just a moment talking about are some of the potential practice-changing trials that may be coming out in 2018. I think that probably one of the most exciting areas for all of us is the area of CAR-T cells. What we hopefully will begin to see is larger patient populations, or phase 2 expansions of some of those phase 1 studies that have looked so encouraging. We may also begin to see other antibody drug conjugates (ADCs) with monoclonal antibodies. We have again seen updates of the phase 1 trial at ASH 2017, and we are looking forward to potentially phase 2 data on that same target as well. Finally, we will continue to watch the many other molecularly targeted trials, as well as updates from some of those smoldering trials where the activity looks very good, but long-term outcomes are probably the important question. There is a lot on the plate in 2018, and stay tuned for additional updates in myeloma. Thank you very much for viewing this activity.

Last modified: January 11, 2018
Related Items by Author
A key educational message from ASH 2017
Sagar Lonial, MD
FAQ Library published on January 12, 2018
Is there a role for Bcl-2 directed treatment for patients with translocation 11;14?
Sagar Lonial, MD
FAQ Library published on October 11, 2017
How will the new IMWG definition of active multiple myeloma impact clinical practice?
Sagar Lonial, MD
FAQ Library published on August 18, 2016
How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?
Sagar Lonial, MD
FAQ Library published on July 18, 2016
What is the role of SPEP, UPEP and immunofixation in managing multiple myeloma patients?
Sagar Lonial, MD
FAQ Library published on July 6, 2016
Is BD or KD a standard of care in relapsed/refractory multiple myeloma?
Sagar Lonial, MD
FAQ Library published on June 15, 2016
Which is the best indicator of improved outcomes in multiple myeloma: sCR, CR, IFCR or MCR?
Sagar Lonial, MD
FAQ Library published on May 10, 2016
What new classes of therapy are emerging for multiple myeloma?
Sagar Lonial, MD
FAQ Library published on March 10, 2016
How does one define high-risk smoldering or asymptomatic multiple myeloma?
Sagar Lonial, MD
FAQ Library published on November 6, 2014
What are the mechanisms of renal complications in patients with multiple myeloma?
Sagar Lonial, MD
FAQ Library published on March 15, 2011 in Comorbidities/SEs